Roth Capital Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Key Points

• Roth Capital initiated coverage of Dianthus Therapeutics with a Buy rating and a $113 price target, implying 42.44% upside from the stock’s $79.33 opening price.
• Analyst sentiment is broadly positive: Dianthus has a “Moderate Buy” consensus rating and an average price target of $128.54, although one analyst rates the stock a Sell.
• Dianthus remains a loss-making clinical-stage biotechnology company; it missed quarterly EPS estimates, while insiders sold approximately $26.1 million of stock during the last quarter.

Equities researchers at Roth Capital began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) in a report released on Tuesday, Briefing.com reports. The firm set a "buy" rating and a $113.00 price target on the stock. Roth Capital's price target indicates a potential upside of 42.44% from the company's current price.

A number of other research analysts have also commented on DNTH. HC Wainwright restated a "buy" rating and set a $158.00 price target on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Raymond James Financial reissued a "strong-buy" rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a report on Friday, September 11th. They issued an "overweight" rating and a $135.00 price objective for the company. Finally, Citigroup began coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They issued a "buy" rating and a $156.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $128.54.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $79.33 on Tuesday. The company's 50-day moving average price is $95.29 and its two-hundred day moving average price is $83.74. Dianthus Therapeutics has a one year low of $32.28 and a one year high of $117.88. The stock has a market capitalization of $4.35 billion, a PE ratio of -19.12 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. On average, analysts anticipate that Dianthus Therapeutics will post -3.81 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares in the company, valued at $326,553.90. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Adam M. Veness sold 16,167 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the transaction, the senior vice president owned 3,833 shares of the company's stock, valued at $423,086.54. The trade was a 80.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 242,429 shares of company stock valued at $26,118,913. Insiders own 3.02% of the company's stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the company. ABS Investment Management LLC acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $194,960,000. First Horizon Corp bought a new position in Dianthus Therapeutics during the 1st quarter valued at $32,000. EFG International AG purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $49,000. GAMMA Investing LLC grew its position in Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company's stock valued at $49,000 after buying an additional 254 shares during the period. Finally, Global Retirement Partners LLC bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $93,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company's research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus' lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.